Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021041886 - MODIFIED N-810 AND METHODS THEREFOR

Publication Number WO/2021/041886
Publication Date 04.03.2021
International Application No. PCT/US2020/048511
International Filing Date 28.08.2020
IPC
C07K 14/54 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins (IL)
C07K 14/715 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
715for cytokines; for lymphokines; for interferons
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/22 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
C07K 14/495
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
495Transforming growth factor [TGF]
C07K 14/5443
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins [IL]
5443IL-15
C07K 16/2827
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2827against B7 molecules, e.g. CD80, CD86
C07K 2317/622
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
62comprising only variable region components
622Single chain antibody (scFv)
C07K 2319/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
01containing a localisation/targetting motif
02containing a signal sequence
C07K 2319/03
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
01containing a localisation/targetting motif
03containing a transmembrane segment
Applicants
  • NANTBIO, INC. [US]/[US]
Inventors
  • NIAZI, Kayvan
  • MCFARLANE, Heather
Agents
  • FESSENMAIER, Martin
  • PHUKAN, Priti
  • BALLEW CHANG, Nicole
  • DEAN, Ryan
Priority Data
62/893,66229.08.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MODIFIED N-810 AND METHODS THEREFOR
(FR) N-810 MODIFIÉ ET PROCÉDÉS ASSOCIÉS
Abstract
(EN)
Compositions and methods for multi-specific protein complexes comprising an interleukin-15 (IL-15) domain comprising an N72D mutation (IL-15N72D), a IL-15 receptor alpha sushi-binding domain (IL-15RαSu), an immunoglobulin Fc domain, and a mutated transforming growth factor-beta receptor type 2 (TGFβRII) domain, wherein the mutated TGFβRII domain has a N-> Q mutation in positions 47, 71, and 131 respectively. The IL-15RαSu domain, the Fc domain, and the mutated TGFβRII domain are sequentially linked by amide bonds. Preferably, contemplated complexes further include a binding domain that specifically binds to a disease antigen, immune checkpoint molecule, or immune signaling molecule.
(FR)
L'invention concerne des compositions et des procédés pour des complexes protéiques multi-spécifiques comprenant un domaine d'interleukine-15 (IL-15) comprenant une mutation N72D (IL-15 N72D), un domaine de liaison alpha sushi du récepteur IL-15 (IL-15RαSu), un domaine Fc d'immunoglobuline et un domaine de récepteur type 2 du facteur de croissance transformant bêta muté (TGFβRII), le domaine TGFβRII muté ayant une mutation N -> Q en positions 47, 71 et 131 respectivement. Le domaine IL-15RαSu, le domaine Fc et le domaine TGFβRII muté sont séquentiellement liés par des liaisons amide. De préférence, les complexes envisagés comprennent en outre un domaine de liaison qui se lie de manière spécifique à un antigène de maladie, une molécule de point de contrôle immunitaire ou une molécule de signalisation immunitaire.
Also published as
Latest bibliographic data on file with the International Bureau